Haemonetics to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Haemonetics (NYSE:HAE) announced that President and CEO Chris Simon will join a fireside chat with investors at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. ET.
A live webcast and 90-day replay will be available via Haemonetics' Investor Relations website.
Positive
- None.
Negative
- None.
News Market Reaction – HAE
In the Jun 3 session, HAE declined 0.74%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 07 | Earnings results posted | Neutral | +3.2% | Fourth quarter fiscal 2026 results posted with webcast and replay details. |
| May 05 | Conference appearance | Neutral | +0.5% | CEO fireside chat at Bank of America 2026 Healthcare Conference announced. |
| Apr 24 | Clinical study data | Positive | +0.5% | 574-patient study showed strong safety and efficacy for VASCADE MVP XL. |
| Apr 01 | Earnings date set | Neutral | +1.1% | Announcement of timing for Q4 and fiscal 2026 results and conference call. |
| Mar 30 | FDA approval | Positive | +2.6% | FDA approval for expanded labeling of VASCADE MVP XL for larger sheaths. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including conferences, earnings, and FDA updates, has typically seen modestly positive price reactions, with no instances of negative 24-hour moves in the provided history.
Over the past months, Haemonetics has combined investor outreach with product and regulatory milestones. Earnings and fiscal 2026 results on May 7 and the prior earnings date announcement both saw positive reactions. Multiple conference appearances, including another major healthcare conference on May 12, 2026, also coincided with small gains. FDA approval and supporting study data for VASCADE MVP XL in March–April delivered additional positive, though measured, price responses. Today’s Goldman Sachs conference participation continues this pattern of ongoing investor engagement alongside a backdrop of recent product and earnings developments.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link:
https://event.webcasts.com/starthere.jsp?ei=1766065&tp_key=0b16b4b62d&tp_special=8
A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Vice President-Investor Relations & Treasury | David Trenk, Sr. Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: | |
Josh Gitelson, Sr. Director-Global Communications | |
(781) 356-9776 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-to-present-at-goldman-sachs-47th-annual-global-healthcare-conference-302788972.html
SOURCE Haemonetics Corporation